TW EN

scroll

Go Top

臺中榮民總醫院 臨床試驗中心Taichung Veterans General Hospital Clinical Trials Center

  • Total Beds1,622
  • Total Doctors934
  • Address1650 Taiwan Boulevard Sec. 4,Xitun,Taichung City 407
  • Phone Number+886-423592525 ext. 4780

1. Smart Healthcare and Decentralized Trial System

2. Development in Cellular Therapy and Innovative Medical Technology

3. Comprehensive Academic Support System from Research Development to Implementation

Site Introduction

Taichung Veterans General Hospital (TCVGH) Clinical Trials Center was established in 2009 and was granted national-level excellence as a clinical trial center in 2024. Through the highest ethical and scientific standards, we promote clinical research with cutting-edge information technology and professional academic support, facilitating medical discoveries and efficacy verification.
We are committed to:
1. Facilitating communication channels between industry sponsors and TCVGH researchers.
2. Providing infrastructure for clinical trials (researchers and facilities).
3. convene IRB consortium in excellent CTCs as well as the other medical centers
4. Promoting international collaboration with academic institutions and industry partners.
5. Maintaining good communication with the Ministry of Health and Welfare's "Clinical Trial Excellence Program" (CTEP).
As Taiwan enters the 21st century, it leaves a profound impression on the world with its enormous potential in medicine, biotechnology, and information technology. In the future, domestic and international pharmaceutical companies, government research institutions, and private entities seeking academic medical centers to validate new diagnostics and therapies will find that TCVGH has positioned itself at the forefront of innovative clinical trials and research.

Clinicl Trial Expertise

Clinical trial for all major organ system disease of all vital organ systems

International Accreditation

美國臨床研究受試者保護評鑑協會AAHRPP認證(Full Reaccreditation)
FERCAP國際認證
美國醫療資訊暨管理系統協會(HIMSS)Stage 7 認證

GCP Inspection/audit

US FDA
Taiwan FDA

What types of clinical trial do you conduct?

Publications

CTC

1

Kim, T. H., Kishimoto, M., Wei, J. C., Jeong, H., Nozaki, A., & Kobayashi, S. (2023). Brodalumab, an anti-interleukin-17 receptor A monoclonal antibody, in axial spondyloarthritis: 68-week results from a phase 3 study. Rheumatology (Oxford, England), 62(5), 1851–1859. https://doi.org/10.1093/rheumatology/keac522

2

Curtis, J. R., Yamaoka, K., Chen, Y. H., Bhatt, D. L., Gunay, L. M., Sugiyama, N., Connell, C. A., Wang, C., Wu, J., Menon, S., Vranic, I., & Gómez-Reino, J. J. (2023). Malignancy risk with tofacitinib versus TNF inhibitors in rheumatoid arthritis: results from the open-label, randomised controlled ORAL Surveillance trial. Annals of the rheumatic diseases, 82(3), 331–343. https://doi.org/10.1136/ard-2022-222543

3

Connelly, K., Kandane-Rathnayake, R., Hoi, A., Louthrenoo, W., Hamijoyo, L., Luo, S. F., Wu, Y. J., Cho, J., Lateef, A., Lau, C. S., Chen, Y. H., Navarra, S., Zamora, L., Li, Z., An, Y., Sockalingam, S., Hao, Y., Zhang, Z., Chan, M., Katsumata, Y., … Morand, E. F. (2023). Association of Modified Systemic Lupus Erythematosus Responder Index Attainment With Long-Term Clinical Outcomes: A Five-Year Prospective Study. Arthritis & rheumatology (Hoboken, N.J.), 75(3), 401–410. https://doi.org/10.1002/art.42350

4

Chang, T. Y., Chao, T. F., Lin, C. Y., Lin, Y. J., Chang, S. L., Lo, L. W., Hu, Y. F., Chung, F. P., & Chen, S. A. (2023). Catheter ablation of atrial fibrillation in heart failure with impaired systolic function: An updated meta-analysis of randomized controlled trials. Journal of the Chinese Medical Association : JCMA, 86(1), 11–18. https://doi.org/10.1097/JCMA.0000000000000823

5

Lin, W. C., Tai, W. C., Chang, C. H., Tu, C. H., Feng, I. C., Shieh, M. J., Chung, C. S., Yen, H. H., Chou, J. W., Wong, J. M., Liu, Y. H., Huang, T. Y., Chuang, C. H., Tsai, T. J., Chiang, F. F., Lu, C. Y., Hsu, W. H., Yu, F. J., Chao, T. H., Wu, D. C., … Wei, S. C. (2023). Real-World Evidence of Effectiveness and Safety of Vedolizumab for Inflammatory Bowel Disease in Taiwan: A Prospective Nationwide Registry (VIOLET) Study. Inflammatory bowel diseases, 29(11), 1730–1740. https://doi.org/10.1093/ibd/izac269

6

Sternberg, C. N., Petrylak, D. P., Bellmunt, J., Nishiyama, H., Necchi, A., Gurney, H., Lee, J. L., van der Heijden, M. S., Rosenbaum, E., Penel, N., Pang, S. T., Li, J. R., García Del Muro, X., Joly, F., Pápai, Z., Bao, W., Ellinghaus, P., Lu, C., Sierecki, M., Coppieters, S., … Quinn, D. I. (2023). FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 41(3), 629–639. https://doi.org/10.1200/JCO.21.02303

7

Chen, J. J., Wu, Y. C., Wang, J. S., & Lee, C. H. (2023). Liposomal bupivacaine administration is not superior to traditional periarticular injection for postoperative pain management following total knee arthroplasty: a meta-analysis of randomized controlled trials. Journal of orthopaedic surgery and research, 18(1), 206. https://doi.org/10.1186/s13018-023-03699-4

8

Jiang, R. S., Yan, K., Chiang, Y. F., & Chiang, P. J. (2023). The Effect of Chinese Herbal Medicine on Traumatic Anosmia: A Prospective, Randomized Clinical Trial. The Laryngoscope, 133(6), 1473–1479. https://doi.org/10.1002/lary.30676

9

Format:

10

Tsai, S. F., Yang, C. T., Liu, W. J., & Lee, C. L. (2023). Development and validation of an insulin resistance model for a population without diabetes mellitus and its clinical implication: a prospective cohort study. EClinicalMedicine, 58, 101934. https://doi.org/10.1016/j.eclinm.2023.101934